{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:12:17Z","timestamp":1760044337102},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,2,18]],"date-time":"2010-02-18T00:00:00Z","timestamp":1266451200000},"content-version":"vor","delay-in-days":1508,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Addict"],"published-print":{"date-parts":[[2006,1,2]]},"abstract":"<jats:p>Understanding the drug interactions between antiretrovirals and opioid therapies may decrease toxicities and enhance adherence with improved HIV outcomes in opioid\u2010dependent individuals. The authors report the results of a clinical pharmacology study designed to determine whether significant pharmacokinetic and\/or pharmacodynamic interactions occur between the non\u2010nucleoside reverse transcriptase inhibitor, delavirdine (DLV), and either methadone or levoalpha acetyl methadol (LAAM) (n = 40). DLV significantly decreased methadone clearance (p = .018) and increased the methadone elimination half\u2010life (p &lt; .001) with a resultant increase in AUC of 19% and C<jats:sub>min<\/jats:sub>of 29%. The combined effect of DLV on the total concentration of LAAM and its active metabolites, nor LAAM and dinor LAAM, was to significantly increase AUC by 43% (p &lt; .001), C<jats:sub>max<\/jats:sub> by 30% (p = .013), and C<jats:sub>min<\/jats:sub> by 59% (p = .004) while decreasing T<jats:sub>max<\/jats:sub> (p = .05). Cognitive deficits over the seven\u2010day study period as measured by the Mini\u2010Mental State Examination, opioid withdrawal symptoms as measured by the Objective Opioid Withdrawal Scale, or complaints of adverse symptoms were not observed. Methadone and LAAM did not affect DLV concentrations. The findings from this study show that DLV treatment in methadone\u2010 or LAAM\u2010maintained individuals results in altered opioid pharmacokinetics with an increased exposure and potential risk for opioid toxicity with methadone or LAAM treatment and an increased risk of cardiac toxicity with concomitant LAAM and DLV administration.<\/jats:p>","DOI":"10.1080\/10550490500419029","type":"journal-article","created":{"date-parts":[[2006,1,31]],"date-time":"2006-01-31T22:07:55Z","timestamp":1138745275000},"page":"23-34","source":"Crossref","is-referenced-by-count":32,"title":["Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Delavirdine"],"prefix":"10.1111","volume":"15","author":[{"given":"Elinore F.","family":"McCance\u2010Katz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petrie M.","family":"Rainey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gene D.","family":"Morse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Friedland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Boyarsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Gourevitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Jatlow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,2,18]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"Responding to Intravenous Drug Use (IDU) among People Living with HIV\/AIDS: An International Review","author":"McCance\u2010Katz EF"},{"key":"e_1_2_6_3_2","first-page":"588","volume-title":"Clinical Textbook of Addictive Disorders","author":"McCance\u2010Katz EF","year":"2005"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.288.2.222","article-title":"Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society\u2014USA Panel","volume":"288","author":"Yeni PG","year":"2002","journal-title":"JAMA"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-5_Part_2-200209031-00001"},{"key":"e_1_2_6_6_2","first-page":"429","article-title":"Interactions between methadone and medications used to treat HIV infection: a review","volume":"67","author":"Gourevitch MN","year":"2000","journal-title":"Mt Sinai J Med"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2001.00342.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199905280-00012"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/376907"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/1055049029008810"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/aja.10.4.296.307"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/10550490490436037"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-9209-6_25"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890423349"},{"issue":"20","key":"e_1_2_6_15_2","first-page":"22","article-title":"The mini\u2010international neuropsychiatric interview (MINI): the development and validation of a structured diagnostic interview for DSM\u2010IV and ICD\u201010","volume":"59","author":"Sheehan DV","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.3109\/00952998709001515"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1694-1699.2003"},{"key":"e_1_2_6_19_2","volume-title":"WinNonlin 1.0 TM [computer program]","year":"1995"},{"key":"e_1_2_6_20_2","volume-title":"Statistical Power Analysis: A Computer Program","author":"Borenstein M","year":"1989"},{"key":"e_1_2_6_21_2","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen J","year":"1988"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199808150-00004"},{"key":"e_1_2_6_23_2","first-page":"631","article-title":"Metabolism of delavirdine, a human immunodeficiency virus type\u20101 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A","volume":"26","author":"Voorman RL","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90133-8"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1021\/tx950116m"},{"key":"e_1_2_6_26_2","first-page":"1347","article-title":"The involvement of cytochrome P 450 3A4 in the n\u2010demethylation of l\u2010alpha\u2010acetylmethadol (LAAM), norLAAM, and methadone","volume":"25","author":"Moody DE","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2001.5054"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1999.9479612.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008X(77)90112-0"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-3623(79)90070-3"},{"key":"e_1_2_6_31_2","first-page":"422","article-title":"General cardiovascular pharmacology of l\u2010alpha\u2010acetylmethadol (LAAM)","volume":"27","author":"Stickney JL","year":"1979","journal-title":"NIDA Res Monogr"},{"key":"e_1_2_6_32_2","unstructured":"European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit Product Safety Announcements.EMEA public statement on levoacetylmethadol (Orlaam)\u2014life\u2010threatening ventricular rhythm disorders.19 December 2000; EMEA\/38918\/00. Available at:http:\/\/www.emea.eu.int\/.Accessed February 27 2004."},{"key":"e_1_2_6_33_2","first-page":"257","article-title":"Inhibition of methadone and buprenorphine n\u2010dealkylations by three HIV\u20101 protease inhibitors","volume":"26","author":"Iribarne C","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_34_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00126334-200106010-00010","article-title":"Effect of ritona\u2010vir\/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401","volume":"27","author":"Gerber JG","year":"2001","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["The American Journal on Addictions"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1080%2F10550490500419029","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1080\/10550490500419029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T18:16:08Z","timestamp":1697566568000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1080\/10550490500419029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1,2]]}},"alternative-id":["10.1080\/10550490500419029"],"URL":"https:\/\/doi.org\/10.1080\/10550490500419029","archive":["Portico"],"relation":{},"ISSN":["1055-0496","1521-0391"],"issn-type":[{"value":"1055-0496","type":"print"},{"value":"1521-0391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,2]]}}}